Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.43 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | IL1B | P01584 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30136032 | 0.83 | CRBN (0.46) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL30135980 | 0.82 | CRBN (0.46) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL30135769 | 0.82 | CRBN (0.49) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL30135727 | 0.81 | CRBN (0.57) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL31044005 | 0.81 | CRBN (0.51) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL30135911 | 0.77 | CRBN (0.49) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL30136011 | 0.76 | CRBN (0.46) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL24474223 | 0.76 | CRBN (0.55) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL2383505 | 0.76 | DDB1 (0.70) | CRBNDDB1IKZF3MAP1LC3BTNF | |
| SCHEMBL29986861 | 0.75 | CRBN (0.58) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-04-10 | — | — | US | disclosed |
| EP-4384520-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023017442-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885IKZF3 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.